Products and pharmaceutical compositions

A method of treating any of the following conditions:

• Parkinson's disease, restless leg tremors, dyskinesias, Huntington's disease, Alzheimer's disease, drug-induced movement disorders, depression, attention deficit disorder, attention deficit hyperactivity disorder, bipolar illness, anxiety, sleep disorder, narcolepsy, cognitive impairment, dementia, Tourette's syndrome, autism, fragile X syndrome, psychostimulant withdrawal, drug addiction, cerebrovascular disease, stroke, congestive heart disease, hypertension, pulmonary hypertension, pulmonary arterial hypertension, sexual dysfunction, asthma, chronic obstructive pulmonary disease, allergic rhinitis, autoimmune and inflammatory diseases;
• female sexual dysfunction, exercise amenorrhoea, anovulation, menopause, menopausal symptoms, pre-menstrual syndrome, premature labor, infertility, irregular menstrual cycles, abnormal uterine bleeding, osteoporosis, multiple sclerosis, prostate enlargement, prostate cancer, hypothyroidism, estrogen-induced endometrial hyperplasia or carcinoma, glaucoma or elevated intraocular pressure, psychosis, psychotic symptoms, hallucinations, paranoid or bizarre delusions, or disorganized speech and thinking, schizophrenia, schizoaffective disorder, schizophreniform disorder, psychotic disorder, delusional disorder, mania in acute manic episodes and bipolar disorder, traumatic brain injury;
• comprising administering an effective amount of (a) PDE1 inhibitor, (6aR,9aS)-5,6a,7,8,9,9a-hexahydro-5-methyl-3-(phenylamino)-2-((4-Pyridin-2yl)-benzyl)-cyclopent[4,5]imidazo[1,2-a]pyrazolo[4,3-e]pyrimidin-4(2H)-one, in free or pharmaceutically acceptable salt form, and (b) PDE2 inhibitor 2-(3,4-Dimethoxybenzyl)-7-{(1R)-1-[(1R)-1-hydroxyethyl]-4-phenylbutyl}-5-methylimidazo[5,1-f][1,2,4]triazin-4(3H)-one (BAY 60-7550), in free or pharmaceutically acceptable salt form, to a patient in need of such treatment, wherein treatment excludes prophylaxis.